Preclinical antivenom-efficacy testing reveals potentially disturbing deficiencies of snakebite treatment capability in East Africa

BACKGROUND: Antivenom is the treatment of choice for snakebite, which annually kills an estimated 32,000 people in sub-Saharan Africa and leaves approximately 100,000 survivors with permanent physical disabilities that exert a considerable socioeconomic burden. Over the past two decades, the high co...

Descripción completa

Detalles Bibliográficos
Autores principales: Harrison, Robert A., Oluoch, George O., Ainsworth, Stuart, Alsolaiss, Jaffer, Bolton, Fiona, Arias, Ana-Silvia, Gutiérrez, José-María, Rowley, Paul, Kalya, Stephen, Ozwara, Hastings, Casewell, Nicholas R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5646754/
https://www.ncbi.nlm.nih.gov/pubmed/29045429
http://dx.doi.org/10.1371/journal.pntd.0005969

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5646754/
https://www.ncbi.nlm.nih.gov/pubmed/29045429
http://dx.doi.org/10.1371/journal.pntd.0005969

Ejemplares similares